Academic Journal
View in EDS
Linked Full Text

Hospitalization Among Pulmonary Arterial Hypertension Patients With and Without Connective Tissue Disease Comorbidities Prescribed Oral Selexipag

Bibliographic Details
Title: Hospitalization Among Pulmonary Arterial Hypertension Patients With and Without Connective Tissue Disease Comorbidities Prescribed Oral Selexipag
Authors: Yuen Tsang, Risho Singh, Sumit Verma, Sumeet Panjabi
Source: Rheumatology and Therapy, Vol 10, Iss 3, Pp 741-756 (2023)
Publisher Information: Adis, Springer Healthcare, 2023.
Publication Year: 2023
Collection: LCC:Diseases of the musculoskeletal system
Subject Terms: Pulmonary arterial hypertension, Selexipag, Connective tissue disease, Health care costs, Diseases of the musculoskeletal system, RC925-935
More Details: Abstract Introduction Patients with connective tissue disorders (CTD) and pulmonary arterial hypertension (PAH) have a poorer prognosis than those with other PAH etiologies. This study assessed the impact of CTD on healthcare outcomes among PAH patients with and without CTD comorbidities that were treated with oral selexipag. Methods The study utilized Optum’s de-identified Clinformatics® Data Mart Database (2007–2021) from January 1, 2014 to June 30, 2019, and identified patients with PAH without CTD and PAH with CTD treated with oral selexipag. Patients had ≥ 12-month baseline period with no requirement for a minimum follow-up period. Patients were followed until any of the following events: discontinuation of oral selexipag, or health plan disenrollment, or death, or presence of a diagnosis claim for CTEPH, or study end date, whichever occurred first. PAH-related hospitalizations, PAH disease progression, and healthcare utilizations and costs were assessed in the follow-up period. The Cox proportional hazards model was used to evaluate the time to hospitalization and generalized linear models were used to examine healthcare costs and utilization between the two cohorts. Results In the analysis, 237 PAH without CTD, and 80 PAH patients with CTD comorbidities prescribed oral selexipag were included. The PAH without CTD comorbidities cohort was older (65 vs. 63 years old), had proportionately less females (72 vs. 83%), and higher comorbidity burden than PAH with CTD comorbidities (mean CCI index 3 vs. 2). After adjusting for potential confounders, the risk for PAH-related hospitalization (hazard ratio (HR) 1.13, p value 0.641), all-cause hospitalization (HR 1.09, p value: 0.765), and PAH disease progression (HR 1.14, p value 0.522) between the two cohorts were similar. After adjusting for baseline demographic and clinical characteristics, PAH with CTD comorbidities incurred higher total mean all-cause PAH-related medical care costs compared to PAH without CTD comorbidities. Conclusions In this real-world study, the risk of hospitalization and PAH disease progression were similar between the two cohorts who received oral selexipag. The results from this study corroborate findings of the GRIPHON post hoc analysis of PAH-associated CTD patients and support oral selexipag use in PAH-CTD patients.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2198-6576
2198-6584
Relation: https://doaj.org/toc/2198-6576; https://doaj.org/toc/2198-6584
DOI: 10.1007/s40744-023-00547-z
Access URL: https://doaj.org/article/b3ae782811fe4d53aefb60b787e2da4c
Accession Number: edsdoj.b3ae782811fe4d53aefb60b787e2da4c
Database: Directory of Open Access Journals
FullText Links:
  – Type: other
    Url: https://resolver.ebsco.com:443/public/rma-ftfapi/ejs/direct?AccessToken=4A5B80CEC14DF2648C23&Show=Object
Text:
  Availability: 0
CustomLinks:
  – Url: https://resolver.ebsco.com/c/xy5jbn/result?sid=EBSCO:edsdoj&genre=article&issn=21986576&ISBN=&volume=10&issue=3&date=20230301&spage=741&pages=741-756&title=Rheumatology and Therapy&atitle=Hospitalization%20Among%20Pulmonary%20Arterial%20Hypertension%20Patients%20With%20and%20Without%20Connective%20Tissue%20Disease%20Comorbidities%20Prescribed%20Oral%20Selexipag&aulast=Yuen%20Tsang&id=DOI:10.1007/s40744-023-00547-z
    Name: Full Text Finder (for New FTF UI) (s8985755)
    Category: fullText
    Text: Find It @ SCU Libraries
    MouseOverText: Find It @ SCU Libraries
  – Url: https://doaj.org/article/b3ae782811fe4d53aefb60b787e2da4c
    Name: EDS - DOAJ (s8985755)
    Category: fullText
    Text: View record from DOAJ
    MouseOverText: View record from DOAJ
Header DbId: edsdoj
DbLabel: Directory of Open Access Journals
An: edsdoj.b3ae782811fe4d53aefb60b787e2da4c
RelevancyScore: 986
AccessLevel: 3
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 986.003051757813
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Hospitalization Among Pulmonary Arterial Hypertension Patients With and Without Connective Tissue Disease Comorbidities Prescribed Oral Selexipag
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Yuen+Tsang%22">Yuen Tsang</searchLink><br /><searchLink fieldCode="AR" term="%22Risho+Singh%22">Risho Singh</searchLink><br /><searchLink fieldCode="AR" term="%22Sumit+Verma%22">Sumit Verma</searchLink><br /><searchLink fieldCode="AR" term="%22Sumeet+Panjabi%22">Sumeet Panjabi</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: Rheumatology and Therapy, Vol 10, Iss 3, Pp 741-756 (2023)
– Name: Publisher
  Label: Publisher Information
  Group: PubInfo
  Data: Adis, Springer Healthcare, 2023.
– Name: DatePubCY
  Label: Publication Year
  Group: Date
  Data: 2023
– Name: Subset
  Label: Collection
  Group: HoldingsInfo
  Data: LCC:Diseases of the musculoskeletal system
– Name: Subject
  Label: Subject Terms
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Pulmonary+arterial+hypertension%22">Pulmonary arterial hypertension</searchLink><br /><searchLink fieldCode="DE" term="%22Selexipag%22">Selexipag</searchLink><br /><searchLink fieldCode="DE" term="%22Connective+tissue+disease%22">Connective tissue disease</searchLink><br /><searchLink fieldCode="DE" term="%22Health+care+costs%22">Health care costs</searchLink><br /><searchLink fieldCode="DE" term="%22Diseases+of+the+musculoskeletal+system%22">Diseases of the musculoskeletal system</searchLink><br /><searchLink fieldCode="DE" term="%22RC925-935%22">RC925-935</searchLink>
– Name: Abstract
  Label: Description
  Group: Ab
  Data: Abstract Introduction Patients with connective tissue disorders (CTD) and pulmonary arterial hypertension (PAH) have a poorer prognosis than those with other PAH etiologies. This study assessed the impact of CTD on healthcare outcomes among PAH patients with and without CTD comorbidities that were treated with oral selexipag. Methods The study utilized Optum’s de-identified Clinformatics® Data Mart Database (2007–2021) from January 1, 2014 to June 30, 2019, and identified patients with PAH without CTD and PAH with CTD treated with oral selexipag. Patients had ≥ 12-month baseline period with no requirement for a minimum follow-up period. Patients were followed until any of the following events: discontinuation of oral selexipag, or health plan disenrollment, or death, or presence of a diagnosis claim for CTEPH, or study end date, whichever occurred first. PAH-related hospitalizations, PAH disease progression, and healthcare utilizations and costs were assessed in the follow-up period. The Cox proportional hazards model was used to evaluate the time to hospitalization and generalized linear models were used to examine healthcare costs and utilization between the two cohorts. Results In the analysis, 237 PAH without CTD, and 80 PAH patients with CTD comorbidities prescribed oral selexipag were included. The PAH without CTD comorbidities cohort was older (65 vs. 63 years old), had proportionately less females (72 vs. 83%), and higher comorbidity burden than PAH with CTD comorbidities (mean CCI index 3 vs. 2). After adjusting for potential confounders, the risk for PAH-related hospitalization (hazard ratio (HR) 1.13, p value 0.641), all-cause hospitalization (HR 1.09, p value: 0.765), and PAH disease progression (HR 1.14, p value 0.522) between the two cohorts were similar. After adjusting for baseline demographic and clinical characteristics, PAH with CTD comorbidities incurred higher total mean all-cause PAH-related medical care costs compared to PAH without CTD comorbidities. Conclusions In this real-world study, the risk of hospitalization and PAH disease progression were similar between the two cohorts who received oral selexipag. The results from this study corroborate findings of the GRIPHON post hoc analysis of PAH-associated CTD patients and support oral selexipag use in PAH-CTD patients.
– Name: TypeDocument
  Label: Document Type
  Group: TypDoc
  Data: article
– Name: Format
  Label: File Description
  Group: SrcInfo
  Data: electronic resource
– Name: Language
  Label: Language
  Group: Lang
  Data: English
– Name: ISSN
  Label: ISSN
  Group: ISSN
  Data: 2198-6576<br />2198-6584
– Name: NoteTitleSource
  Label: Relation
  Group: SrcInfo
  Data: https://doaj.org/toc/2198-6576; https://doaj.org/toc/2198-6584
– Name: DOI
  Label: DOI
  Group: ID
  Data: 10.1007/s40744-023-00547-z
– Name: URL
  Label: Access URL
  Group: URL
  Data: <link linkTarget="URL" linkTerm="https://doaj.org/article/b3ae782811fe4d53aefb60b787e2da4c" linkWindow="_blank">https://doaj.org/article/b3ae782811fe4d53aefb60b787e2da4c</link>
– Name: AN
  Label: Accession Number
  Group: ID
  Data: edsdoj.b3ae782811fe4d53aefb60b787e2da4c
PLink https://login.libproxy.scu.edu/login?url=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.b3ae782811fe4d53aefb60b787e2da4c
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s40744-023-00547-z
    Languages:
      – Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 16
        StartPage: 741
    Subjects:
      – SubjectFull: Pulmonary arterial hypertension
        Type: general
      – SubjectFull: Selexipag
        Type: general
      – SubjectFull: Connective tissue disease
        Type: general
      – SubjectFull: Health care costs
        Type: general
      – SubjectFull: Diseases of the musculoskeletal system
        Type: general
      – SubjectFull: RC925-935
        Type: general
    Titles:
      – TitleFull: Hospitalization Among Pulmonary Arterial Hypertension Patients With and Without Connective Tissue Disease Comorbidities Prescribed Oral Selexipag
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Yuen Tsang
      – PersonEntity:
          Name:
            NameFull: Risho Singh
      – PersonEntity:
          Name:
            NameFull: Sumit Verma
      – PersonEntity:
          Name:
            NameFull: Sumeet Panjabi
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 03
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-print
              Value: 21986576
            – Type: issn-print
              Value: 21986584
          Numbering:
            – Type: volume
              Value: 10
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: Rheumatology and Therapy
              Type: main
ResultId 1